Cancer Immunotherapy

Accellvecs Inc. provides a novel cancer immunotherapy technology using the autologous tumor cell vector (SynVC).

​

Features of SynVC

1. SynVC is a regenerative medicine product in which a cancer patient's own tumor cells are encapsulated with a natural killer T (NKT) cell activating compound, and then cell death is induced in the tumor cells. 

2. When SynVC is returned to a cancer patient's body, induces the antitumor effects of both dendritic cells (DCs) and NKT cells in the body.

3. The therapy can be started at just one week after receiving the patient's cells.